HomeFilePharmacology

Pharmacology

View Category

Acute coronary syndromes

Acute Coronary Syndrome: What Is Safer, Antiaggregant Monotherapy or De-Escalation?

For several years it has been shown that 12-month dual antiplatelet therapy (DAPT) is mandatory for patients...
solaci -
Learn More
Acute coronary syndromes

Cangrelor: Additional Research Findings Not Translating into Clinical Practice

The potent and fast endovenous platelet inhibition provided by Cangrelor reduces ischemic events early in the course...
solaci -
Learn More
Antiplatelet

Clnical Practice Dissociated from Study Outcomes: Bad News for Our Patients?

Differences in patient characteristics, changes in treatment algorithms, and advances in device technology, together or separately, might...
solaci -
Learn More
Antithrombotic Anticoagulants

Left Atrial Appendage Closure vs Direct Anticoagulants at Long Term

The PRAGUE-17 has shown that left atrial appendage closure is not inferior to direct anticoagulants at long...
solaci -
Learn More
Acute coronary syndromes

TICO: Age Impacts the Effect of Antiplatelet Monotherapy

The higher the age, the greater the benefit of ticagrelor monotherapy vs. dual antiplatelet therapy (DAPT) in...
solaci -
Learn More
Institutional News

The Most Relevant Articles of 2021 in Pharmacology

This last year, new data in pharmacology gave way to changes in practices and new hypotheses, when...
solaci -
Learn More
Antiplatelet

Post-PCI Ticagrelor Monotherapy in High-Risk Bleeding

In patients at high risk of bleeding undergoing coronary PCI and after completing 3-month DAPT with no...
solaci -
Learn More
Institutional News

The Most Read Articles of 2021: Pharmacology

A new year is coming to an end and at SOLACI we are going over the most...
solaci -
Learn More